AstraZeneca PLC ADR

Yahoo Finance • 12 days ago

AstraZeneca Reverses As Beat And Raise Outweighs Drug Smuggling Claims

AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, and AstraZeneca stock rose despite a criminal probe in China. Continue reading View comments... Full story

Yahoo Finance • last month

With 72% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backing

Key Insights Given the large stake in the stock by institutions, AstraZeneca's stock price might be vulnerable to their trading decisions A total of 25 investors have a majority stake in the company with 49% ownership Insiders have bought... Full story

Yahoo Finance • 2 months ago

AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline

AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline On Monday, AstraZeneca plc (NASDAQ:AZN) entered into an exclusive license agreement with Hong Kong-based CSPC Pharmaceutical Group Ltd to adva... Full story

Yahoo Finance • 2 months ago

AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review

AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing application for Calquence (acala... Full story

Yahoo Finance • 2 months ago

Is AstraZeneca PLC (NASDAQ:AZN) The Top Global Stock To Buy Now?

We recently made a list of the 10 Best Global Stocks To Buy Now. In this piece, we will look at where AstraZeneca PLC (NASDAQ:AZN) ranks among the top ten global stocks to buy. With the third quarter of 2024 ending, the discourse on the s... Full story

Yahoo Finance • 3 months ago

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst HC Wainwright initiated coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) and noted the company as an emerging biotech compa... Full story

Yahoo Finance • 3 months ago

Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population Presidential Symposium for NeoCO... Full story

Yahoo Finance • 3 months ago

AstraZeneca staff detained in China amid claims of illegal drug imports

A vial and a syringe are seen in front of a displayed AstraZeneca logo Five AstraZeneca staff have been detained in China amid claims of potential illegal activity at the British drug giant. Authorities in Shenzhen, China, are investigat... Full story

Yahoo Finance • 3 months ago

AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024

Presidential Symposium will demonstrate how proprietary computational pathology biomarker for TROP2 enhances patient selection and potentially predicts patient outcomes in advanced lung cancer Presidential Symposium for NIAGARA will highl... Full story

Yahoo Finance • 3 months ago

AstraZeneca PLC (AZN): A Good 52-Week High Stock to Buy According to Short Sellers

We recently compiled a list of the 14 Best 52-Week High Stocks to Buy According to Short Sellers.In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other 52-week high stocks. The U.S. sto... Full story

Yahoo Finance • 3 months ago

AstraZeneca PLC (AZN): A Cheap Pharmaceutical Stock to Buy According to Short Sellers

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Short Sellers.In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other cheap pharmaceutical stocks. T... Full story

Yahoo Finance • 3 months ago

George Soros Amplifies S&P 500 ETF Trust Holdings in Q2 2024

Insight into Soros Fund Management's Latest Strategic Moves George Soros (Trades, Portfolio), the renowned financier and chair of Soros Fund Management LLC, has made significant adjustments to his investment portfolio in the second quarte... Full story

Yahoo Finance • 3 months ago

AstraZeneca PLC (LON:AZN) Shares Could Be 49% Below Their Intrinsic Value Estimate

Key Insights The projected fair value for AstraZeneca is UK£255 based on 2 Stage Free Cash Flow to Equity AstraZeneca is estimated to be 49% undervalued based on current share price of UK£129 The US$142 analyst price target for AZN is 44%... Full story

Yahoo Finance • 3 months ago

Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows

Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows Researchers from the Universities of Cambridge, Bristol, and Edinburgh hav... Full story

Yahoo Finance • 4 months ago

Here’s Why AstraZeneca PLC (AZN) Increased in Q2

Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund declined 2.55% (Institutional Shares) in the quarter compared t... Full story

Yahoo Finance • 5 months ago

3 No-Brainer Stocks to Buy for Under $100 Right Now

A low price doesn't necessarily mean low quality. That's true with lots of products and services. And it's true with stocks, too. We asked Three Motley Fool contributors to name no-brainer healthcare stocks to buy for under $100 right now... Full story

Yahoo Finance • 6 months ago

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for t... Full story

Yahoo Finance • 6 months ago

3 No-Brainer Stocks to Buy in June

You're probably familiar with the old adage, "April showers bring May flowers." And you probably know the punchline to the question, "What do May flowers bring?" (The answer: Pilgrims.) But what does June bring? Three Motley Fool contribu... Full story

Yahoo Finance • 6 months ago

AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock

As two of the world's largest and most prolific drugmakers, Pfizer(NYSE: PFE) and AstraZeneca(NASDAQ: AZN) both have grand visions for how to grow even larger over the coming years. And with billions of dollars devoted to research and deve... Full story

Yahoo Finance • 6 months ago

Why Is AstraZeneca Stock Trading Lower On Tuesday?

Why Is AstraZeneca Stock Trading Lower On Tuesday? On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial. Topline ove... Full story